The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease

The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area

The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

Study Overview

• Status: Unknown
• Conditions: COVID-19; Perception, Self; Facilities and Services Utilization
• Intervention / Treatment: Other: Interview

Detailed Description

Background: In the epidemic area of COVID-19, emergency treatment of chronic diseases other than COVID-19 can be limited. Therefore, it is important to reduce the risk of exposure to COVID-19 in patients with chronic immune diseases such as IBD, but it is most important to manage well so that the underlying diseases are not exacerbated at times when emergency medical treatment may be difficult. However, there is a lack of evidence on the management policy of chronic immune diseases in the current epidemic, and only expert opinions are being presented.

Aim: To investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital utilization.

Material and method: This study is a multicenter, prospective, cross-sectional survey which will be consulted in Keimyung University Dongsan Medical Center and Yeungnam University Hospital. Patients with IBD aged above 18 will enrolled and surveyed about their perception about COVID-19 and status of hospital utilization during pandemic period. Patients' demographics and disease-related variables will be evaluated to identify clinical significances.

• Study Type: Observational
• Enrollment (Anticipated): 800

Contacts and Locations

Study Locations

• Korea, Republic of
  • Jung-gu
    • Daegu, Jung-gu, Korea, Republic of, 700-712
      • Recruiting
      • KeimyungUniversity
      • Contact: Yoo Jin Lee; Phone Number: +82-250-7088; Email: doctorlyj@naver.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

This study population will comprise the sample of all patients with inflammatory bowel disease, living in the Daegu city

Description

Inclusion Criteria:

• Patients with inflammatory growth disease, those who agreed to participate in this study

Exclusion Criteria:

• Those who are unable to understand or answer the questionnaire
• Those who declined to participate in this study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Inflammatory bowel disease; Patients with inflammatory bowel disease who live in COVID-19 hyperemic area	Other: Interview; Surveys on medical use patterns and patient's perceptions about COVID-19

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient's perception of COVID-19 and medical use patterns	Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period	1day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exacerbation of symptoms	Exacerbation of symptoms in patients with IBD during the pandemic period	1day

Collaborators and Investigators

• Sponsor: Keimyung University Dongsan Medical Center
• Collaborators: Yeungnam University College of Medicine
• Investigators: Principal Investigator: Yoojin Lee, M.D., Keimyung University Dongsan Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): April 24, 2020
• Primary Completion (Anticipated): March 30, 2021
• Study Completion (Anticipated): March 30, 2021

Study Registration Dates

• First Submitted: May 12, 2020
• First Submitted That Met QC Criteria: May 12, 2020
• First Posted (Actual): May 13, 2020

Study Record Updates

• Last Update Posted (Actual): May 13, 2020
• Last Update Submitted That Met QC Criteria: May 12, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; COVID-19; Inflammatory Bowel Diseases
• Other Study ID Numbers: 2020-04-070

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No